Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials

JAMA Ophthalmology

Volumn 132, Issue 8, 2014, Pages 915-921

  Ying, Gui Shuang ^a   Kim, Benjamin J ^a   Maguire, Maureen G ^a   Huang, Jiayan ^a   Daniel, Ebenezer ^a   Jaffe, Glenn J ^b   Grunwald, Juan E ^a   Blinder, Kevin J ^c   Flaxel, Christina J ^d   Rahhal, Firas ^e   Regillo, Carl ^f   Martin, Daniel F ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BARNES RETINA INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^f WILLS EYE HOSPITAL   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; GEOGRAPHIC ATROPHY; HUMAN; INCIDENCE; INTRARETINAL FLUID; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETINA FOVEA SCARRING; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT ABNORMALITY; RETINAL THICKENING; RETINAL THINNING; SCAR FORMATION; SUBRETINAL HYPERREFLECTIVE MATERIAL; SUBRETINAL NEOVASCULARIZATION; SUSTAINED VISUAL ACUITY LOSS; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INCIDENCE; MACULAR DEGENERATION; MIDDLE AGED; VISUAL ACUITY;

EID: 84907312621     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.1019     Document Type: Article

References (15)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
2. Brown DM, Kaiser PK, MichelsM, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, NasirMA, GiustMJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372, e5.
5. Martin DF,Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
6. Martin DF,Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
7. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7): 1399-1411.
8. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118 (3):523-530.
9. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. Am J Ophthalmol. 2012;153(6):1116-1124, e1.
10. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol. 2011;151(5):887-895, e1.
11. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
12. Grunwald JE, Daniel E, Ying GS, et al; CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2012;119(8): 1634-1641.
13. DeCroos FC, Toth CA, Stinnett SS, Heydary CS, Burns R, Jaffe GJ; CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2012;119(12):2549-2557.
14. Jaffe GJ, Martin DF, Toth CA, et al. Association of macular morphology with visual acuity in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2013;120 (9):1860-1870.
15. Ying GS, Huang J,Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122-129.